NP 2

Drug Profile

NP 2

Alternative Names: NET-ENK; NP2; NP2 Enkephalin; NTDDS expressing enkephalin; PGN-202

Latest Information Update: 03 Jun 2015

Price : $50

At a glance

  • Originator Diamyd Medical
  • Developer Periphagen Holdings
  • Class Analgesics; Gene therapies
  • Mechanism of Action Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cancer pain

Most Recent Events

  • 01 Nov 2013 Diamyd completes a phase II trial in Cancer pain in USA (NCT01291901)
  • 30 Apr 2013 Diamyd Medical is now called Mertiva
  • 12 Oct 2012 NP 2 is available for licensing as of 28 Oct 2010.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top